In vitro characterisation of [
C595
Lutetium-177
MUC1
Pancreatic cancer
Radioimmunotherapy
Journal
EJNMMI radiopharmacy and chemistry
ISSN: 2365-421X
Titre abrégé: EJNMMI Radiopharm Chem
Pays: England
ID NLM: 101714628
Informations de publication
Date de publication:
14 Aug 2023
14 Aug 2023
Historique:
received:
07
06
2023
accepted:
02
08
2023
medline:
14
8
2023
pubmed:
14
8
2023
entrez:
14
8
2023
Statut:
epublish
Résumé
Pancreatic ductal adenocarcinoma (PDAC) continues to be a malignancy with an unmet clinical demand. Development of radioimmunoconjugates which target cancer-specific receptors provides an opportunity for radioimmunotherapy of both metastatic and primary PDAC. In this study, we characterised the in vitro behaviour of a novel beta-emitting radioimmunoconjugate [ A series of in vitro experiments were performed on PDAC cell lines (PANC-1, CAPAN-1, BxPC-3 and AsPC-1) exhibiting strong to weak MUC1-CE expression. [ [
Sections du résumé
BACKGROUND
BACKGROUND
Pancreatic ductal adenocarcinoma (PDAC) continues to be a malignancy with an unmet clinical demand. Development of radioimmunoconjugates which target cancer-specific receptors provides an opportunity for radioimmunotherapy of both metastatic and primary PDAC. In this study, we characterised the in vitro behaviour of a novel beta-emitting radioimmunoconjugate [
RESULTS
RESULTS
A series of in vitro experiments were performed on PDAC cell lines (PANC-1, CAPAN-1, BxPC-3 and AsPC-1) exhibiting strong to weak MUC1-CE expression. [
CONCLUSION
CONCLUSIONS
[
Identifiants
pubmed: 37578571
doi: 10.1186/s41181-023-00204-4
pii: 10.1186/s41181-023-00204-4
pmc: PMC10425306
doi:
Types de publication
Journal Article
Langues
eng
Pagination
18Subventions
Organisme : PanKind, The Australian Pancreatic Cancer Foundation
ID : 2019 Avner Innovation Grant
Organisme : Australian Nuclear Science and Technology Organisation
ID : 2021 ANSTO/ANZSNM Research Grant
Organisme : Australian Government
ID : Research Training Program Scholarship
Informations de copyright
© 2023. Springer Nature Switzerland AG.
Références
J Nucl Med. 2001 May;42(5):726-32
pubmed: 11337567
J Oncol. 2022 Jul 7;2022:8549487
pubmed: 35847365
Cell. 2020 Apr 2;181(1):151-167
pubmed: 32243788
EJNMMI Phys. 2020 Feb 10;7(1):8
pubmed: 32040783
Expert Rev Endocrinol Metab. 2011 Nov;6(6):835-848
pubmed: 22201009
J Biol Chem. 1988 Sep 15;263(26):12820-3
pubmed: 3417635
PLoS One. 2018 Feb 20;13(2):e0193260
pubmed: 29462213
Gastroenterology. 2022 Aug;163(2):386-402.e1
pubmed: 35398344
Cell Res. 2018 Jan;28(1):9-21
pubmed: 29076500
Cancer Biol Ther. 2008 Jan;7(1):76-80
pubmed: 18347423
Int J Mol Sci. 2021 Jun 18;22(12):
pubmed: 34207342
Gynecol Oncol. 2007 Jun;105(3):695-702
pubmed: 17368732
JAMA. 2021 Sep 7;326(9):851-862
pubmed: 34547082
Br J Cancer. 1990 May;61(5):681-6
pubmed: 1692469
PLoS One. 2011;6(9):e24405
pubmed: 21931707
J Hematol Oncol. 2012 Oct 26;5:68
pubmed: 23102107
World J Gastroenterol. 2018 Sep 28;24(36):4164-4177
pubmed: 30271081
Oncogenesis. 2016 Jan 18;5:e185
pubmed: 26779808
J Clin Med. 2018 Jan 04;7(1):
pubmed: 29300345
Biol Pharm Bull. 2008 Dec;31(12):2288-93
pubmed: 19043215
Am J Cancer Res. 2017 Jun 01;7(6):1372-1383
pubmed: 28670497
Biochem Soc Trans. 2018 Jun 19;46(3):659-668
pubmed: 29784646
N Engl J Med. 2021 Sep 16;385(12):1091-1103
pubmed: 34161051
N Engl J Med. 2011 May 12;364(19):1817-25
pubmed: 21561347
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Cancers (Basel). 2020 Feb 19;12(2):
pubmed: 32092952
Biochem Biophys Res Commun. 2011 Feb 18;405(3):377-81
pubmed: 21219855
Urol Res. 2001 Feb;29(1):13-9
pubmed: 11310209
Mol Cancer. 2013 Nov 20;12(1):143
pubmed: 24257318
Surgery. 2014 Jun;155(6):977-88
pubmed: 24856119
Biomed Res Int. 2013;2013:871936
pubmed: 23509794
N Engl J Med. 2017 Jan 12;376(2):125-135
pubmed: 28076709
Cancers (Basel). 2020 Dec 28;13(1):
pubmed: 33379259
Int J Mol Sci. 2018 Jul 09;19(7):
pubmed: 29987260
Cancer Biol Ther. 2005 Aug;4(8):848-53
pubmed: 16082185
Cancer Immunol Immunother. 2006 Nov;55(11):1337-47
pubmed: 16485130
Antibodies (Basel). 2022 Jul 12;11(3):
pubmed: 35892707
J Immunol. 2008 Sep 1;181(5):3116-25
pubmed: 18713982
Lancet Oncol. 2016 Jun;17(6):801-810
pubmed: 27160474
Nucl Med Biol. 2009 May;36(4):395-402
pubmed: 19423007
Br J Cancer. 2004 Dec 13;91(12):2086-93
pubmed: 15599383
Front Oncol. 2021 Jul 27;11:670396
pubmed: 34386419
Cancers (Basel). 2010 Oct 25;2(4):1794-812
pubmed: 24281201
Eur J Nucl Med. 1997 Apr;24(4):439-43
pubmed: 9096097
Ann Surg. 2021 Jan 1;273(1):154-162
pubmed: 30921051
Cells. 2022 Sep 24;11(19):
pubmed: 36230945
Bioconjug Chem. 2009 Oct 21;20(10):1975-82
pubmed: 19785403